What Is New in Metabolic Dysfunction-Associated Steatotic Liver Disease in Lean Individuals: From Bench to Bedside-Reference-Cited by-同舟云学术

What Is New in Metabolic Dysfunction-Associated Steatotic Liver Disease in Lean Individuals: From Bench to Bedside

Published:2024-01-03 Issue:1 Volume:13 Page:278
ISSN:2077-0383
Container-title:Journal of Clinical Medicine
language:en
Short-container-title:JCM

Author:

Danpanichkul Pojsakorn¹,Suparan Kanokphong¹^ORCID,Kim Donghee²^ORCID,Wijarnpreecha Karn³⁴^ORCID

Affiliation:

1. Immunology Unit, Department of Microbiology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand

2. Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94305, USA

3. Division of Gastroenterology and Hepatology, Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ 85004, USA

4. Department of Internal Medicine, Banner University Medical Center, Phoenix, AZ 85006, USA

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects more than 30% of the world’s adult population. While it is associated with obesity and metabolic syndrome, emerging evidence has shown that a substantial number of MASLD patients have a normal body mass index (“lean individuals with MASLD”). In this article, we provide an overview of the definition, epidemiology, pathogenesis, and clinical outcomes associated with lean individuals with MASLD and updates on current management.

Publisher

MDPI AG

Link

https://www.mdpi.com/2077-0383/13/1/278/pdf

Reference81 articles.

1. Changing trends of liver transplantation and mortality from non-alcoholic fatty liver disease;Majumdar;Metabolism,2020

2. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review;Younossi;Hepatology,2023

3. The silent burden of non-alcoholic fatty liver disease in the elderly: A global burden of disease analysis;Danpanichkul;Aliment. Pharmacol. Ther.,2023

4. Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States;Younossi;Clin. Gastroenterol. Hepatol.,2021

5. Danpanichkul, P., Kongarin, S., Permpatdechakul, S., Polpichai, N., Duangsonk, K., Manosroi, W., Chaiyakunapruk, N., Mousa, O.Y., Kim, D., and Chen, V.L. (2023). The Surreptitious Burden of Nonalcoholic Fatty Liver Disease in the Elderly in the Asia-Pacific Region: An Insight from the Global Burden of Disease Study 2019. J. Clin. Med., 12.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epidemiology of gastrointestinal cancers: a systematic analysis from the Global Burden of Disease Study 2021;Gut;2024-09-06

2. Upregulation of fatty acid synthesis genes in the livers of adolescent female rats caused by inhalation exposure to PCB52 (2,2′,5,5′-Tetrachlorobiphenyl);Environmental Toxicology and Pharmacology;2024-09

3. Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019;Metabolism;2024-09

4. Mortality outcomes in individuals with MASLD versus MASLD and increased alcohol intake;Journal of Gastroenterology and Hepatology;2024-08-22

5. Changes in the epidemiological trends of primary liver cancer in the Asia–Pacific region;Scientific Reports;2024-08-22